“The current predicament has uncovered some structural weaknesses in the EU’s medicines provide chain and also a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides mentioned. She advisable that supply chain difficulties be resolved in an EU pharmaceutical tactic expected to be introduced by the end i